Abstract
Insulin-induced weight gain, often occurring over the first 9-12 months after starting insulin in patients with type 2 diabetes (T2DM), is obviously undesirable in an already overweight population and may offset the beneficial effects of insulin. We hypothesized that addition of liraglutide may be especially effective in reversing body weight in patients with pronounced insulin-associated weight gain while preserving glycemic control. This hypothesis was tested in a randomized controlled trial (ELEGANT).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
